Spots Global Cancer Trial Database for KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors
Official Title: Investigator Initiated, Phase 2 Clinical Trial of Selinexor (KPT-330) for the Treatment of Poorly Differentiated Lung and Gastroenteropancreatic Tumors
Study ID: NCT02250885
Conditions
Interventions
Study Description
Brief Summary: Evaluate the efficacy of Selinexor in patients with poorly differentiated lung and gastrointestinal and pancreatic neuroendocrine tumors.
Detailed Description: Evaluate the efficacy of Selinexor in patients with poorly differentiated lung and gastrointestinal and pancreatic neuroendocrine tumors in adult patients age \>/= to 18.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Gabrail Cancer Center Research, Canton, Ohio, United States
Contact Details
Name: Nashat Y Gabrail, MD
Affiliation: Gabrail Cancer Center Research
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
